Transcriptional effects of PBRM1 mutation have recently been identified in analysis of the association of response of ccRCC to immune checkpoint therapies [31], and may have a similar effect in enhancing response to rapalogs. This evidence concerns the gene PBRM1 and nonpapillary renal cell carcinoma.